Literature DB >> 10986554

Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect.

T W Weickert1, T E Goldberg, J M Gold, L B Bigelow, M F Egan, D R Weinberger.   

Abstract

BACKGROUND: Although intellectual and neurocognitive deficits accompany schizophrenia, there are inconsistencies in the literature concerning issues of intellectual decline, premorbid deficits, a modal deficit pattern, and preserved abilities.
METHODS: A battery of neuropsychological tests was administered once to 117 consecutively admitted patients with chronic schizophrenia and a group of 27 healthy control subjects to examine patterns of premorbid and current intellect (measured by means of reading scores and IQ, respectively) and the attendant cognitive profiles in schizophrenia using classification methods based on clinically derived (IQ levels) and atheoretical (cluster) techniques.
RESULTS: Sixty patients (51%) with schizophrenia who displayed a general intellectual decline of 10 points or greater from estimated premorbid levels also exhibited deficits of executive function, memory, and attention. Twenty-eight patients (23%) with consistently low estimated premorbid intellect and current intellectual levels who displayed no evidence of IQ decline exhibited language and visual processing deficits in addition to deficits present in the intellectually declining group. The remaining 29 patients (25%) who displayed average estimated premorbid intellectual levels did not show IQ decline and exhibited a cognitive profile similar to normal, with the exception of executive function and attention impairment. Atheoretical analyses support the findings from clinically derived subgroups.
CONCLUSIONS: These results suggest that IQ decline, although modal in schizophrenia, is not universally characteristic and that executive function and attention deficits may be core features of schizophrenia, independent of IQ variations.

Entities:  

Mesh:

Year:  2000        PMID: 10986554     DOI: 10.1001/archpsyc.57.9.907

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  140 in total

1.  Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study.

Authors:  Konasale M Prasad; Shaun M Eack; Dhruman Goradia; Krishna M Pancholi; Matcheri S Keshavan; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Am J Psychiatry       Date:  2011-06-01       Impact factor: 18.112

2.  Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input.

Authors:  Thomas W Weickert; Alejandro Terrazas; Llewellyn B Bigelow; James D Malley; Thomas Hyde; Michael F Egan; Daniel R Weinberger; Terry E Goldberg
Journal:  Learn Mem       Date:  2002 Nov-Dec       Impact factor: 2.460

3.  Anterior limb of the internal capsule in schizophrenia: a diffusion tensor tractography study.

Authors:  Gudrun Rosenberger; Paul G Nestor; Jungsu S Oh; James J Levitt; Gordon Kindleman; Sylvain Bouix; Jennifer Fitzsimmons; Margaret Niznikiewicz; Carl-Fredrik Westin; Ron Kikinis; Robert W McCarley; Martha E Shenton; Marek Kubicki
Journal:  Brain Imaging Behav       Date:  2012-09       Impact factor: 3.978

4.  Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls.

Authors:  Dwight Dickinson; Terry E Goldberg; James M Gold; Brita Elvevåg; Daniel R Weinberger
Journal:  Schizophr Bull       Date:  2010-03-29       Impact factor: 9.306

5.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 6.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

8.  The Impact of Childhood Adversity on Cognitive Development in Schizophrenia.

Authors:  Ruth Wells; Isabella Jacomb; Vaidy Swaminathan; Suresh Sundram; Danielle Weinberg; Jason Bruggemann; Vanessa Cropley; Rhoshel K Lenroot; Avril M Pereira; Andrew Zalesky; Chad Bousman; Christos Pantelis; Cynthia Shannon Weickert; Thomas W Weickert
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

9.  Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.

Authors:  Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman
Journal:  Schizophr Res       Date:  2018-08-02       Impact factor: 4.939

10.  DTNBP1 genotype influences cognitive decline in schizophrenia.

Authors:  Katherine E Burdick; Terry E Goldberg; Birgit Funke; John A Bates; Todd Lencz; Raju Kucherlapati; Anil K Malhotra
Journal:  Schizophr Res       Date:  2006-10-30       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.